Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder with an immune-mediated pathophysiology that affects the central nervous system (CNS). Like other autoimmune conditions, it has a predilection for female gender. This suggests a gender bias and a possible hormonal association. Inflammation and demyelination are hallmarks of MS. Oligodendrocytes are the myelinating cells of the CNS and these continue to be generated by oligodendrocyte precursor cells (OPCs). The process of remyelination represents a major form of plasticity in the developing adult CNS. Remyelination does occur in MS, but the process is largely inadequate and/or incomplete. Current treatment strategies primarily focus on reducing inflammation or immunosuppression, but there is a need for more extensive research on re-myelination as a possible mechanism of treatment. Previous studies have shown that pregnancy leads to an increase in OPC proliferation, oligodendrocyte generation and the number of myelinated axons in the maternal CNS. Studies have also suggested that this remyelination is possibly mediated by estriol. Sex hormones in particular have been shown to have an immuno-protective effect in TH1-driven autoimmunity diseases. The aim of our article is to review the available research on sex hormone-specific immune modulatory effects, assess its remyelination potential in MS, and suggest a future path for more extensive research on sex hormone as a target for therapeutics in MS.

1.
Berger A: Science commentary: Th1 and Th2 responses: what are they? BMJ 2000; 321: 424–424.
2.
Tesmer LA, Lundy SK, Sarkar S, et al: Th17 cells in human disease. Immunol Rev 2008; 223: 87–113.
3.
Soldan SS, Alvarez Retuerto AI, Sicotte NL, et al: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003; 171: 6267–6274.
4.
Luessi F, Kuhlmann T, Zipp F: Remyelinating strategies in multiple sclerosis. Expert Rev Neurother 2014; 14: 1315–1334.
5.
Vrachnis N, Zygouris D, Iliodromiti Z, et al: Probing the impact of sex steroids and menopause-related sex steroid deprivation on modulation of immune senescence. Maturitas 2014; 78: 174–178.
6.
Velardi E, Dudakov JAvan den Brink: MRM sex steroid ablation: an immunoregenerative strategy for immunocompromised patients. Bone Marrow Transplant 2015; 50:S77–S81.
7.
Patas K, Engler JB, Friese MA, et al: Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity. J Reprod Immunol 2013; 97: 140–146.
8.
Zenclussen AC: Adaptive immune responses during pregnancy. Am J Reprod Immunol 2013; 69: 291–303.
9.
Confavreux C, Hutchinson M, Hours MM, et al: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 1998; 339: 285–291.
10.
De Leon-Nava MA, Nava K, Soldevila G, et al: Immune sexual dimorphism: effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation. J Steroid Biochem Mol Biol 2009; 113: 57–64.
11.
Grossman CJ, Roselle GA, Mendenhall CL: Sex streriod regulation of autoimmunity. J Steroid Biochem Mol Biol 1991; 40: 649–659.
12.
Aristimuno C, Teijeiro R, Valor L, et al: Sex-hormone receptors pattern on regulatory T-cells: clinical implications for multiple sclerosis. Clin Exper Med 2012; 12: 247–255.
13.
Zhu ML, Bakhru P, Conley B, et al: Sex bias in CNS autoimmune disease mediated by androgen control of autoimmune regulator. Nat Commun 2016; 7: 11350.
14.
Furman D, Hejblum BP, Simon N, et al: Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A 2014; 111: 869–874.
15.
Schuurs AH, Dietrich H, Gruber J, et al: Effects of sex steroid analogs on spontaneous autoimmune thyroiditis in obese strain chickens. Int Arch Allergy Immunol 1992; 97: 337–344.
16.
Kipp M, Beyer C: Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 2009; 30: 188–200.
17.
Luchetti S, van Eden CG, Schuurman K, et al: Gender differences in multiple sclerosis: Induction of estrogen signaling in male and progesterone signaling in female lesions. J Neuropathol Exp Neurol 2014; 73: 123–135.
18.
Cohen JH, Danel L, Cordier G, et al: Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol 1983; 131: 2767–2771.
19.
Miller L, Hunt JS: Sex steroid hormones and macrophage function. Life Sci 1996; 59: 1–14.
20.
Trenova AG, Slavov GS, Manova MG, et al: Female sex hormones and cytokine secretion in women with multiple sclerosis. Neurol Res 2013; 35: 95–99.
21.
Simard J, Gingras S: Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol Cell Endocrinol 2001; 171: 25–40.
22.
Glatigny S, Bettelli E: Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS). Cold Spring Harb Perspect Med 2018;pii:a028977.
23.
Benedek G, Zhang J, Nguyen H, et al: Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. J Neuroimmunol 2017; 305: 59–67.
24.
Bodhankar S, Wang C, Vandenbark AA, et al: Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol 2011; 41: 1165–1175.
25.
Van den Broek HH, Damoiseaux JG, De Baets MH, et al: The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review. Mult Scler 2005; 11: 349–359.
26.
Haghmorad D, Amini AA, Mahmoudi MB, et al: Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells. J Neuroimmunol 2014; 277: 85–95.
27.
Howell OW, Rundle JL, Garg A, et al: Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neuro. 2010; 69: 1017–1033.
28.
Drew PD, Chavis JA, Bhatt R: Sex Steroid Regulation of Microglial Cell Activation: Relevance to Multiple Sclerosis; in Panzica G, Melcangi RC (eds): Steroids and the Nervous System. International Meeting on Steroids and the Nervous System (2nd : 2003 : Turin, Italy). New York, New York Acad Sciences, 2003, pp 329–334.
29.
Habib P, Dreymueller D, Ludwig A, et al: Sex steroid hormone-mediated functional regulation of microglia-like BV-2 cells during hypoxia. J Steroid Biochem Mol Biol 2013; 138: 195–205.
30.
Habib P, Slowik A, Zendedel A, et al: Regulation of hypoxia-Induced inflammatory responses and M1-M2 phenotype switch of primary rat microglia by sex steroids. J Mol Neurosci 2014; 52: 277–285.
31.
Trabattoni D, Saresella M, Pacei M, et al: Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different Patterns of disease. J Immunol 2009; 183: 4984–4993.
32.
Bodhankar S, Offner H: PD-1 interaction with PD-L1 but not PD-L2 on B-cells mediates protective effects of estrogen against EAE. J Immunol 2013; 4: 143.
33.
Gold SM, Sasidhar MV, Morales LB, et al: Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest 2009; 89: 1076–1083.
34.
Kurth F, Luders E, Sicotte NL, et al: Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage Clin 2014; 4: 454–460.
35.
Stangel M, Kuhlmann T, Matthews PM, et al: Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat Rev Neurol 2017; 13: 742–754.
36.
Kipp M, Berger K, Clarner T, et al: Sex steroids control neuroinflammatory processes in the brain: relevance for acute ischaemia and degenerative demyelination. J Neuroendocrinol 2012; 24: 62–70.
37.
Ziehn MO, Avedisian AA, Dervin SM, et al: Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest 2012; 92: 1234–1245.
38.
Correale J, Arias M, Gilmore W: Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1998; 161: 3365–3374.
39.
Elloso MM, Phiel K, Henderson RA, et al: Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol 2005; 185: 243–252.
40.
Spence RD, Voskuhl RR: Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol 2012; 33: 105–115.
41.
Tiwari-Woodruff S, Voskuhl RR: Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neurol Sci 2009; 286: 81–85.
42.
Itoh N, Kim R, Peng M, et al: Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis. J Neuroimmunol 2017; 304: 63–71.
43.
Behjati S, Frank MH: The Effects of tamoxifen on immunity. Curr Med Chem 2009; 16: 3076–3080.
44.
Crabtree-Hartman E: Sex differences in multiple sclerosis. Mult Scler 2010; 16: 193–210.
45.
Kipp M, Hochstrasser T, Schmitz C, et al: Female sex steroids and glia cells: impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network. Neurosci Biobehav Rev 2016; 67: 125–136.
46.
Kumar P, Kale RK, McLean P, et al: Protective effects of 17β estradiol on altered age related neuronal parameters in female rat brain. Neurosci Lett 2011; 502: 56–60.
47.
Pratap UP, Patil A, Sharma HR, et al: Estrogen-induced neuroprotective and anti-inflammatory effects are dependent on the brain areas of middle-aged female rats. Brain Res Bull 2016; 124: 238–253.
48.
Fuller A, Yahikozawa H, So EY, et al: Castration of male C57L/J mice increases susceptibility and estrogen treatment restores resistance to Theiler’s virus-induced demyelinating disease. J Neurosci Res 2007; 85: 871–881.
49.
Trooster WJ, Teelken AW, Kampinga J, et al: Suppression of acute experimental allergic encephalomyelitis by the synthetic sex hormone 17-alpha-ethinylestradiol: an immunological study in the lewis rat. Int Arch Allergy Immunol 1993; 102: 133–140.
50.
Patel R, Moore S, Crawford DK, et al: Attenuation of corpus callosum axon myelination and remyelination in the absence of circulating sex hormones. Brain Pathol 2013; 23: 462–475.
51.
Behl C, Holsboer F: The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci 1999; 20: 441–444.
52.
Tomassini V, Onesti E, Mainero C, et al: Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005; 76: 272–275.
53.
Ali ES, Mangold C,Peiris AN: Estriol: emerging clinical benefits. Menopause 2017; 24: 1081–1085.
54.
Palaszynski KM, Liu H, Loo KK, et al: Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol 2004; 149: 84–89.
55.
Papenfuss TL, Powell ND, McClain MA, et al: Estriol generates tolerogenic dendritic cells In vivo that protect against autoimmunity. J Immunol 2011; 186: 3346–3355.
56.
Zang YC, Halder JB, Hong J, et al: Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol 2002; 124: 106–114.
57.
Goodman MP: Are all estrogens created equal? A review of oral vs. Transdermal therapy. J Womens Health (Larchmt) 2012; 21: 161–169.
58.
De Nicola AF, Coronel F, Garay LI, et al: Therapeutic effects of progesterone in animal models of neurological disorders. CNS Neurol Disord Drug Targets 2013; 12: 1205–1218.
59.
Garay L, Gonzalez Deniselle MC, Sitruk-Ware R, et al: Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 2014; 276: 89–97.
60.
Babri S, Mehrvash F, Mohaddes G, et al. Effect of intrahippocampal administration of Vitamin C and progesterone on learning in a model of multiple sclerosis in rats. Adv Pharm Bull 2015; 5: 83–87.
61.
El-Etr M, Rame M, Boucher C, et al: Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortex. Glia 2015; 63: 104–117.
62.
Daugherty DJ, Selvaraj V, Chechneva OV, et al: A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med 2013; 5: 891–903.
63.
Garay L, Leicaj ML, Deniselle MCG, et al: Neurosteroidogenesis is recovered by progesterone treatment of experimental autoimmune encephalomyelitis and during spontaneous remyelination in the cuprizone model of demyelination. Glia 2017; 65:E420–E421.
64.
Garay L, Gonzalez Giqueaux P, Guennoun R, et al: Progesterone treatment modulates mRNA OF neurosteroidogenic enzymes in a murine model of multiple sclerosis. J Steroid Biochem Mol Biol 2017; 165: 421–429.
65.
Garay L, Gonzalez Deniselle MC, Lima A, et al: Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 2007; 107: 228–237.
66.
Garay L, Gonzalez Deniselle MC, Meyer M, et al: Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res 2009; 1283: 177–185.
67.
Deniselle MCG, Garay L, Meyer M, et al: Experimental and clinical evidence for the protective role of progesterone in motoneuron degeneration and neuroinflammation. Horm Mol Biol and Clin Investig 2011; 7: 403–411.
68.
Chitnis T: The role of testosterone in MS risk and course. Mult Scler 2018; 24: 36–41.
69.
Bove R, Musallam A, Healy BC, et al: Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler 2014; 20: 1584–1592.
70.
Sicotte NL, Giesser BS, Tandon V, et al: -Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007; 64: 683–688.
71.
Gold SM, Chalifoux S, Giesser BS, et al: Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation 2008; 5: 32.
72.
Ziehn MO, Avedisian AA, Dervin SM, et al: Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease. J Neurosci 2012; 32: 12312–12324.
73.
Weinstock-Guttman B, Gallagher E, Baier M, et al: Risk of bone loss in men with multiple sclerosis. Mult Scler 2004; 10: 170–175.
74.
Garay L, Gonzalez Deniselle MC, Gierman L, et al: Pharmacotherapy with 17?-estradiol and progesterone prevents development of mouse experimental autoimmune encephalomyelitis. Horm Mol Biol Clin Investig 2010; 1: 43–51.
75.
Kipp M, Amor S, Krauth R, et al: Multiple sclerosis: Neuroprotective alliance of estrogen-progesterone and gender. Front Neuroendocrinol 2012; 33: 1–16.
76.
Bansil S, Lee HJ, Jindal S, et al: Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol Scand 1999; 99: 91–94.
77.
Rolf L, Damoiseaux J, Hupperts R, et al: Network of nuclear receptor ligands in multiple sclerosis: Common pathways and interactions of sex-steroids, corticosteroids and vitamin D3-derived molecules. Autoimmun Rev 2016; 15: 900–910.
78.
Correale J, Balbuena Aguirre ME, Farez MF: Sex-specific environmental influences affecting MS development. Clin Immunol 2013; 149: 176–181.
79.
Jansson L, Olsson T, Holmdahl R: Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol 1994; 53: 203–207.
80.
Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al: Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric 2017; 20: 285–289.
81.
Benedek G, Zhang J, Nguyen H, et al: Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. J Neuroimmunol 2017; 310: 51–59.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.